Steel Dynamics expects third quarter 2026 earnings between $5.34 and $5.38 per diluted share, up from $3.69 in Q2 2026 and $2.74 in Q3 2025. The increase is driven by higher steel margins, record shipments, and strong demand across construction, energy, automotive, and industrial sectors. Aluminum operations also show improvement with new production lines coming online. The company repurchased $261 million in stock during Q3 and anticipates continued growth into 2027 supported by infrastructure spending and manufacturing investment.
Steel Dynamics' third quarter 2026 earnings guidance is provided as context for readers. For those following the Basic Materials sector, here is Pluang's market snapshot as of Sep 18, 2026 03:24 WIB: of 31 priced US stocks, 26 rose and 5 fell today. Notable movers include AngloGold Ashanti Limited (AU) at USD 102.71 with a 1-day change of +2.98%, BHP Billiton Limited (BHP) at USD 86.58 with +2.90%, and Agnico Eagle Mines Ltd (AEM) at USD 201.00 with +2.78%.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
